Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Open-label Rollover Study of Doravirine/Islatravir in HIV-1 Infection
2020-001191-14Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of doravirine and islatravir in Human immunodeficiency virus infection type 1, sponsored by Merck & Co. Primary endpoint: Serious adverse events at Week 48. Started Jun 2021; status: active.
02
Drugs
doravirineislatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2020-001191-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001191-14.